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Abstract
Background: Collision tumors are rare entities that consist of two histologically distinct tumor types arising in the
same anatomic site. An association between chronic lymphocytic leukemia (CLL) and malignant melanoma (MM)
has been already described. Up to now, they have been documented only at positive regional lymph nodes while
we focused on collision tumor in a skin lesion.
Case presentation: We characterized the genomic profile of a skin CLL/MM collision tumor in a patient with a 9-
years story of CLL. Typical high-grade genomic biomarkers featured the CLL: the immunoglobulin heavy variable
genes were unmutated; a clonal del(11q), involving ATM and BIRC3, was present in the peripheral blood (PB) and
skin lesion, while a subclonal large del(13q)/D13S319-RB1 was detected only in the PB. Interestingly, the del(13q)
clone, increased from 10% to 46% from diagnosis to relapse. NOTCH1, SF3B1, and TP53 were wild type. The MM
lesion carried a BRAFV600E and a TERT promoter mutation.
As the family story was consistent with a genetic predisposition to cancer, we performed mutational analysis of
genes involved in familial melanoma and CLL, and of BRCA1 and BRCA2. No germinal mutation known to
predispose to CLL, MM, or breast cancer was found. Interestingly, conventional cytogenetic detected a
constitutional t(12;17)(p13;p13).
Conclusions: Our data are consistent with distinct genetic landscape of the two tumors which were characterized
by specific disease-related abnormalities. CLL cells carried poor prognostic imbalances, i.e. large deletions of the
long arm of chromosomes 11 and 13, while in MM cells two functionally linked mutations, i.e. BRAFV600E and a TERT
promoter occurred. Although, known germline variations predisposing to MM and/or CLL were ruled out, genetic
counseling suggested the proband family was at high risk for MM.
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Background
CLL, the most frequent hematological disease in adults,
is characterized by a marked variable outcome, from an
indolent clinical course to more aggressive forms with
acquisition of chemo-resistance, after a benign onset.
CLL evolution is largely dependent upon molecular and
cytogenetic features which are well recognized
prognostic markers [1, 2]. Of note, 30–35% of long-term
CLL survivors are at high risk of developing secondary
neoplasms mostly epithelial. This susceptibility do not
appear to depend on anti-neoplastic treatment as the
same incidence of leukemia was observed in treated and
untreated patients [3]. Namely, CLL patients have a
four-fold increase in the risk of developing MM com-
pared with the general population.
MM and CLL collision tumors were reported, as occa-
sional findings, in metastatic lymph nodes of patients
with cutaneous MM [4, 5]. A collision tumor is defined
as the occurrence of two neoplastic cell populations in
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close proximity to each other, though maintaining separ-
ate boundaries. Combination of solid and hematological
neoplasms, such as colon or breast carcinoma or MM,
in conjunction with non-Hodgkin lymphoma or CLL,
are the most frequent association [6, 7].
We report the molecular-cytogenetic characterization
of a unique case of CLL and MM collision tumors. Our
molecular findings are consistent with an independent
origin of the two tumors and suggest that both a familial
predisposition and the CLL-associated immune dysregu-
lation might have played a role in their onset.
Case presentation
At diagnosis of CLL (Rai stage I; Binet stage B), the
patient, a 58 year-old male, had 20.150/mmc white blood
cells with 75% lymphocytes. The bone marrow (BM) bi-
opsy showed a diffuse pattern of infiltration by small
CD20, CD5, CD23, CD38, and ZAP70 positive lymphoid
elements with unmutated immunoglobulin heavy chain.
The patient was treated with 6 cycles of fludarabine, cyclo-
phosphamide, and rituximab, achieving hematological re-
mission. He relapsed after 79 months from diagnosis with
marked lymphocytosis (211.100/mmc) and widespread
lymphadenopathy; PET scan assessed lymph nodes hyper-
activity (SUV max 6.1). At this time, the patient presented
a 17 × 13 mm skin lesion plus twenty-three ~5 mm lesions
on the right side of the trunk. Histology and immunohis-
tochemical features of the main lesion and in-transit me-
tastasis were consistent with a diagnosis of collision CLL
and MM tumors. The MM lesion infiltrated the epidermal
layer and the reticulis dermis (Breslow thickness of
3,4 mm; mitosis 3/mm2) and showed pigmentation, re-
gression, and ulceration. The MM was classified as stage
T3N2M0. The underlying dermis, and partially the hypo-
dermis, were infiltrated by small CD20, CD5, CD23 posi-
tive, CD3 and cyclin D1 negative lymphoid cells (Fig. 1).
MM treatment consisted of wide local excision of the
primary lesion, surgical dissection of 71 axillary lymph
nodes (all positive for CLL involvement), and electroche-
motherapy with intravenous injection of bleomycin for
three times, which elicit a short lasting complete remis-
sion (9 months) of skin lesions. CLL treatment consisted
of 6 cycles of bendamustine and rituximab which in-
duced the hematological remission of CLL.
At MM relapse, a combined treatment with BRAF
(dabrafenib) and MEK (trametinib) inhibitors was




The family story satisfied the criteria of familial melan-
oma as two first-degree relatives, the proband and his
brother developed MM [8]. In particular, the brother
was affected by 4 cutaneous MM. Additionally, the pro-
band’s mother and sister had both suffered of breast
cancer, at the age of 49 and 51, respectively (Fig. 2a).
Genetic testing was performed by Ion Personal Genome
Machine® (PGM™) Sequencer (Thermo Fisher Scientific
Inc., Monza, Italy) using a custom familial melanoma
panel including BAP1, CDKN2A, CDK4, TERT promoter
(pTERT), MITF exon 10, ATM, PALB2, and POT1; TER-
F2IP and ACD, also known to be involved in familial
CLL [9]. Sanger’s sequencing investigated BRCA1 and
BRCA2 and validated next generation sequencing find-
ings (3500 Genetic Analyzer-Life Technologies, Monza,
Italy). Constitutional karyotype of the proband and his
brother and sister, was done on phytohaemagglutinin
(PHA) stimulated peripheral blood (PB) T-lymphocytes.
Molecular-cytogenetic studies
All studies were carried out in accordance with the
Declaration of Helsinki. Written informed consent was
obtained from the patient for publication of clinical his-
tory and any additional related information. The study
was approved by the Bioethics Committee of the Univer-
sity of Perugia (prot. Number 2014–019).
A specific CLL panel probes (LSI ATM SO/CEP11 SG,
LSI TP53 SO/CEP17 SG, LSI D13S319/LSI 13q34/CEP12
Multi-color probe set, LSI 13 RB1 SO, LSI D13S319 SO
and LSI IgH dual color break-apart; Vysis Abbott, Milan,
Italy), was applied on PB samples taken at diagnosis and
relapse, and on formalin-fixed paraffin embedded skin le-
sion after marking the MM and CLL areas according to
haematoxylin/eosin staining. Home-made probes were
also used to investigate the 11q region, by BIRC3/11q22.2
(RP11-605B8) and DDX10/11q22.3 (RP11-244G23), and
the RB1/13q14.2 (RP11-305D15, RP11-174I10) (UCSC
Genome Browser, Human/Feb.2009 GRCh37/hg19). Ana-
lysis was carried out on 200 nuclei/100 cells per experi-
ment with fluorescence microscopy using an Olympus
BX61 (Olympus, Milan, Italy) equipped with a JAI camera
(Copenhagen, Denmark) and CytoVision 4.5.4 software
(Genetix, New Milton, Hampshire, UK). CLL and MM
areas were analyzed separately.
Hot-spot mutations of BRAF, pTERT, SF3B1, NOTCH1,
and the whole coding region of TP53 were studied by De-
naturing High Performance Liquid Chromatography
(DHPLC) and/or Sanger’s sequencing of genomic DNA
samples extracted from skin biopsy after macro-dissection
to separate MM from CLL.
Results
FISH (fluorescent in situ hybridization) analysis of the CLL
skin lesion detected a monoallelic del(11)(q23) with loss of
a large 11q region, involving ATM and BIRC3 (Fig. 2c). Be-
sides del(11)(q23), PB samples also carried a del(13q).
Double-color FISH assay combining probes for common
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deleted region D13S319 and RB1 demonstrated that two
distinct clones were present: 10% of cells had a small
del(13q)/D13S319; 3% of cells had a large del(13q) involving
both RB1 and D13S319 (Fig. 2d, e). The two clones in-
creased at relapse to 46% and 13%, respectively. The CLL-
associated genomic rearrangements were not detected in
the MM skin lesion. No mutations of NOTCH1, SF3B1,
and TP53 were found. The MM cells carried a BRAFV600E
and a pTERT c.1–57 A >C mutation.
The familial melanoma panel did not detect known
predisposing gene variations. BRCA1 and BRCA2 were
wild type.
Discussion
This study reports, for the first time, a collision CLL/
MM tumor of the skin, and the molecular-cytogenetic
background underlying the two tumors. Collision
tumors occurr very rarely, and the association of CLL
and MM have been sporadically found, at metastatic
lymph nodes, of patients with MM [4, 5].
Our molecular and cytogenetic studies showed that the
CLL and the MM had distinct genetic landscapes. The CLL
skin lesion and PB samples were wild type for recurrent
CLL associated mutations and shared high risk biomarkers.
Namely, unmutated IgH variable regions and monoallelic
del(11)(q23). ATM is known to be involved in DNA repair
processes that are altered when deletion and/or ATM loss-
of-function mutations occur; BIRC3, a negative regulator of
alternative NFkB signaling pathway, is implicated in the
modulation of different cellular processes, such as apop-
tosis, cell proliferation, invasion and metastasis, inflamma-
tory and mitogenic kinase signaling. Several lines of
evidence indicate that ATM biallelic deletions and/or loss-
of-function mutations are poor prognostic markers
Fig. 1 Immunohistochemical characterization of skin lesion. a Haematoxylin/eosin staining, ×4. b Haematoxylin/eosin staining, ×10, the dotted black
line defines the border area between CLL and MM tumors. c, d and e Immunohistochemical positivity for CD20, CD5 and CD23 antigens. f
Immunohistochemical negativity for CD3. g Presence of mutant BRAF only in MM lesion. h MIB1 expression to evaluate the neoplastic proliferation
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correlating with a significantly reduced overall survival,
while BIRC3 haplo-insufficiency does not appear to have a
prognostic value [10].
Besides del(11)(q22-q23), PB samples also carried a
del(13q), which is the most common cytogenetic aberra-
tion in CLL, occurring in ~40% of cases and, when iso-
lated, and it’s regarded as good prognostic marker.
However, the amount of leukemic cells bearing the
del(13q) as well as the extension of the deleted region,
appeared to influence patient’s outcome [11]. Moreover,
large del(13q) which include the RB1 oncosuppressor
gene, called “type II” deletions, were associated with gen-
ome complexity [12]. In our case, FISH showed that
both the D13S319 locus and RB1 were lost as expected
in cases with progressive disease and both clones in-
creased at relapse (Fig. 2d, e).
Negative for CLL-associated genomic losses, the MM
carried a BRAFV600E and a pTERT c.1–57 A > C
Fig. 2 Clinical and molecular data of CLL/MM collision tumor. a Pedigree of patient’s family. The proband is indicated by a black arrow. b
Constitutional patient karyotype showed the t(12;17)(p13;p13) in all metaphases analyzed [20]. The 12 and 17 derivative chromosomes are indicated by
red arrows. c Interphase FISH shows ATM monoallelic deletion (red signal referred to target gene and green signal referred to centromere 11). The
abnormal and normal nucleus are indicated by white arrows. d Metaphase FISH of the 13q14 region (D13S319) (red signal) and the RB1 gene (green
signal). The arrows indicate the abnormal derivative chromosome 13 with loss of D13S319 region, and the normal chromosome 13. e Interphase FISH
of the 13q14 region (D13S319) (red signal) and the RB1 gene (green signal). The white arrows show a nucleus with loss of both D13S319 region and RB1
gene, and a nucleus without deletion. f Nucleotidic sequence of BRAF (exon 15) with hot-spot mutation (p.V600E) on melanoma lesion (black arrow).
g Nucleotidic sequence of TERT promoter mutation (1–57 A > C) on melanoma lesion (black arrow)
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mutation (Fig. 2f, g). It is worth mentioning that pTERT
mutations occur as germline, in familial MM, or ac-
quired in sporadic MM [13]. The majority of pTERT
mutations occurr at c.1–124 C > T and c.1–146 C > T
positions, and both generate binding motifs for the Ets/
TCF transcription factors. The pTERT c.1–57 A > C
mutation, of our case, was previously reported in familial
MM and in bladder tumors [13].
The BRAFV600E is an early genomic lesion, occurring in
melanocytic nevi, not sufficient to drive a full-blown
malignant phenotype, while pTERT mutations emerge in
intermediate lesions and melanoma in situ. A functional
link between BRAF and pTERT mutations has been dem-
onstrated since the RAS-ERK signaling, in BRAFV600E
positive melanomas, is critical for regulating active chro-
matin state and recruitment of RNA polymerase II at mu-
tant pTERT. Notably, the mutant pTERT is a key substrate
downstream of the RAS-ERK pathway [14].
As expected, a combined treatment with dabrafenib
and trametinib induced a complete regression of MM
skin lesions, which is still maintained (after 12 months
of treatment). Whether these inhibitors were also effect-
ive against CLL, could not be assessed in our patient,
since he had already undergone chemotherapy. However,
the use of BRAF/MEK inhibitors, in CLL, might be
exploited as new therapeutic approach since BRAF exon
15 mutations have been found in ~3% of cases [15].
Seeking for inherited cancer predisposition, we uncov-
ered that the proband’s brother had suffered of multiple
MM and both the mother and the sister of breast can-
cer. However, although genetic counseling suggested a
family predisposition (Fig. 2a), we ruled out known
germinal mutations of genes involved in these types of
hereditary tumors. Interestingly, the patient had a con-
stitutional t(12;17)(p13;p13), not detected in his brother
and sister. Even though rare familial CLL were linked to
chromosome translocations, the role of this new trans-
location in collision CLL/MM onset of our cases, could
not be determined [16].
Conclusions
In conclusion, we reported for the first time, a case of
collision CLL/MM tumors in a skin lesion [17]. While
our molecular-cytogenetic studies proved that specific
and distinct genetic events selectively underlie the two
lesions, i.e. 11q and 13q deletions for the CLL, and
BRAFV600E and pTERT mutations for the MM, other
reports have shown that the two tumors share the same
lesion. Although, genetic counseling suggested a familial
risk to MM, investigating known gene variations predis-
posing to MM was not informative. Thus, an inherited
condition along with a long lasting story of immune
dysregulation might have cooperated in the CLL/MM
collision tumour onset of our case.
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